Maximal androgen blockade and maximal androgen blockade combined with 125I brachytherapy for prostatic cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 434-435, 2003.
Artigo
em Chinês
| WPRIM
| ID: wpr-238004
ABSTRACT
<p><b>OBJECTIVE</b>To assess the effect of the maximal androgen blockade(MAB) and MAB combined with 125I brachytherapy on prostatic cancer.</p><p><b>METHODS</b>Forty-four patients with prostatic cancer (from 1993 to 2002), 28 at pathologic stage C and 16 at stage D, were analyzed retrospectively. Thirty-five of them were treated by bilateral orchidectomy and anti-androgen drugs, i.e. MAB, and 9 treated by MAB combined with 125I brachytherapy. The survival rates and the variation of serum prostate-specific antigen (PSA) levels between pre- and post-treatment were compared.</p><p><b>RESULTS</b>The level of PSA decreased from 60.3 micrograms/L to 12.1 micrograms/L in 35 patients treated by MAB, and from 72.1 micrograms/L to 3.6 micrograms/L in 9 patients treated by MAB combined with 125I brachytherapy after 6 months. The post-treatment survival rates were 81.3% (26/32, excluding 3 deaths by other diseases) for patients treated by MAB after a mean follow-up of 39.2 (9-84) months and 100% for patients by MAB combined with 125I brachytherapy after a mean follow-up of 13(7-24) months.</p><p><b>CONCLUSION</b>MAB and MAB combined with 125I brachytherapy are effective for patients with prostatic cancer.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias da Próstata
/
Terapêutica
/
Braquiterapia
/
Taxa de Sobrevida
/
Estudos Retrospectivos
/
Mortalidade
/
Terapia Combinada
/
Usos Terapêuticos
/
Antagonistas de Androgênios
/
Radioisótopos do Iodo
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Limite:
Idoso
/
Aged80
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
National Journal of Andrology
Ano de publicação:
2003
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS